Clifford Cele

Email: clifford.cele@outlook.com

Skills

R, RStudio, R Markdown, SAS, LATEX, Overleaf, Microsoft Office Suite, Excel, Word, PowerPoint, Visual Basic for Applications (VBA), Python, jupyter notebook, NumPy, Pandas, Matplotlib, Seaborn, Ploty, SciPy, SciKit-Learn (SKLearn), BeautifulSoup, Visual Studio Code (VS Code), HTML, Javascript, D3.js, Svelte, Git, GitHub, Google Colaboratory.

Education

- **KU Leuven**, Belgium (2019-Currently) Master of Science in Statistics and Data Science: Biometrics
- **Ithaca College**, USA (2010-2014) Bachelor of Arts in Physics and Mathematics

Work Experience

Company: Evidera, Waltham, MA, USA (2014-2019)
Team: Evidence Synthesis, Modeling, & Communication (Health Economics)
Positions: Research Assistant, Research Associate I-III, Project Manager

- Building health economic models to conduct cost-effectiveness and budget impact analyses of healthcare interventions using decision-analytic models (e.g., decision trees, Markov state-transition, and survival partition).
- Programming models using Microsoft Excel with Visual Basic for Applications (VBA).
- Assisting with literature reviews with an emphasis on extracting data relevant to health economic evaluations and cost-effectiveness analyses.
- Drafting project deliverables (e.g., user guides, model specifications, and technical reports) and drafting abstracts, posters, manuscripts, presentations, responses to requests for proposals (RFP).
- Participating in client meetings and drafting meeting minutes.
- Project Management: tracking budgets and expenses, and monitoring timelines and deliverables for projects.
- Leading training sessions for junior staff members on model user interfaces (e.g., how to build user-friendly Excel models for clients).

Publications & Presentations

- Hernandez, L., Lanitis, T., **Cele, C.,** Toro-Diaz, H., Gibson, A., & Kuznik, A. (2018). Intravitreal aflibercept versus ranibizumab for wet age-related macular degeneration: a cost-effectiveness analysis. Journal of managed care & specialty pharmacy, 24(7), 608-616.
- Nalysnyk, L., Sugarman, R., **Cele, C.,** Uyei, J., & Ward, A. (2018). Budget impact analysis of eliglustat for the treatment of gaucher disease type 1 in the United States. Journal of managed care & specialty pharmacy, 24(10), 1002-1008.
- Ruiz, L., Machado, M., Toro-Diaz, H., **Cele, C.,** Hernandez, L., & Harrington, A. (2017). Cost Effectiveness Analysis of Dimethyl Fumarate Versus Teriflunomide for The Treatment of Multiple Sclerosis. Value in Health, 20(9), A724.
- Ruiz L., Toro-Diaz H., **Cele C.,** Hernandez L., Harrington A. Cost-Effectiveness Analysis of Peginterferon Beta-1a versus First-line Injectable Disease-Modifying Therapies for the Treatment of Relapse-Remitting Multiple Sclerosis in Spain. Poster; Presented at ISPOR 20th Annual European Congress – 2017; November 4-8, 2017; Glasgow, Scotland.